CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma - Summary - MDSpire
From the Journals

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

Share

Researchers at The University of Texas MD Anderson Cancer Center have discovered that CD40 overexpression may serve as a prognostic biomarker for angioimmunoblastic T-cell lymphoma (AITL). AITL, a rare subtype of non-Hodgkin lymphoma, is challenging to diagnose and treat due to its heterogeneous microenvironment. Using single-cell RNA sequencing and immunofluorescence, the study revealed that neoplastic T follicular helper cells may adopt a T follicular–regulatory program, contributing to diagnostic ambiguity. These findings suggest that CD40 could help assess patient risk and inform treatment strategies.

Original Source(s)

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

  • by Wendy LaGrego

  • April 22, 2026

Related Content

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min
Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?

IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to uncover the year’s defining breakthroughs

  • April 22, 2026

  • 1 min